Prevention of viral infections in families of recipients of solid organs
M. M. Kaabak,
N. N. Rappoport,
Yu. N. Vyunkova,
Yu. B. Shepetun,
A. G. Trofimova,
E. Yu. Dyakonova,
S. A. Khmyzov https://doi.org/10.33667/2078-5631-2021-18-20-22
Abstract
Current COVID-19 pandemic demands improvements in antiviral prophylaxis. Tyloron, as biological interferon activator, has been synthesized in the 70th of previous century. We used Tyloron in 60 patients – relatives and partners living together with solid organ transplant recipients – in autumn 2020, during second wave of the SARS-CoV‑2 pandemic. Results were compared with 60 patients used other means of antiviral prophylaxis. In patients taking Tyloron the number of febrile episodes was significantly lower (р < 0.02).
About the Authors
M. M. Kaabak
National Medical Research Centre for Children's Health
Russian Federation
Russian Federation
Kaabak Mikhail M., DM Sci, prof., head of Organ Transplant Dept.
Moscow
N. N. Rappoport
National Medical Research Centre for Children's Health
Russian Federation
Russian Federation
Rappoport Nadezhda N., PhD Med, deputy head of Organ Transplant Dept.
Moscow
Yu. N. Vyunkova
National Medical Research Centre for Children's Health
Russian Federation
Russian Federation
Vyunkova Yulia N., pediatrician of Organ Transplant Dept.
Moscow
Yu. B. Shepetun
National Medical Research Centre for Children's Health
Russian Federation
Russian Federation
Shepetun Yulia B., nephrologist of Renal Replacement Therapy Dept
Moscow
A. G. Trofimova
National Medical Research Centre for Children's Health
Russian Federation
Russian Federation
Trofimova Arina G., nephrologist of Renal Replacement Therapy Dept
Moscow
E. Yu. Dyakonova
National Medical Research Centre for Children's Health
Russian Federation
Russian Federation
Dyakonova Elena Yu., DM Sci, chief physician
Moscow
S. A. Khmyzov
National Medical Research Centre for Children's Health
Russian Federation
Russian Federation
Khmyzova Svetlana A., acting head of Renal Replacement Therapy Dept
Moscow
References
1. Krueger R. F., Mayer G. D. Tilorone hydrochloride: an orally active antiviral agent (англ.). Science: journal. 1970. September (Vol. 169, No. 951). P. 1213–1214. PMID 4317923.
2. Mayer G. D., Krueger R. F. Tilorone hydrochloride: mode of action (англ.). Science. 1970. September (Vol. 169, No. 951). P. 1214–1215. PMID 4317924.
3. Kaufman H. E., Centifanto Y. M., Ellison E. D., Brown D. C. Tilorone hydrochloride: human toxicity and interferon stimulation (англ.). Proc Soc Exp Biol Med (англ.) русск.: journal. 1971. Vol. 137, No. 1. P. 357–560. PMID 5581674.
4. Ermol'eva Z.V., Korneeva L. E., Balezina G. I., Nikolaeva O. V., Gvazava I. S. Tilorone as an interferon inducer (неопр.). Antibiotiki. 1973. V. 18, Т. 6. P. 517–520. PMID 4204946.
5. Litvinova L. A., Bogatsky A. V., Gren A. I., Lempart G. V. On the synthesis of 2,7-bis-[2-(diethylamino)ethoxy]fluorenone‑9 (Russian). Reports of the Academy of Sciences of the Ukrainian SSR: journal. 1976. No. 7. P. 610–612.
Review
For citations:
Kaabak M.M., Rappoport N.N., Vyunkova Yu.N., Shepetun Yu.B., Trofimova A.G., Dyakonova E.Yu., Khmyzov S.A. Prevention of viral infections in families of recipients of solid organs. Medical alphabet. 2021;(18):20-22. (In Russ.) https://doi.org/10.33667/2078-5631-2021-18-20-22
Views:
393
Email this article 